Transition metal complexes and photodynamic therapy from a tumor-centered approach: challenges, opportunities, and highlights from the development of TLD1433

S Monro, KL Colon, H Yin, J Roque III, P Konda… - Chemical …, 2018 - ACS Publications
Transition metal complexes are of increasing interest as photosensitizers in photodynamic
therapy (PDT) and, more recently, for photochemotherapy (PCT). In recent years, Ru (II) …

From bench to bedside–preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis (1H-indazole) ruthenate (III)](KP1019 or …

CG Hartinger, S Zorbas-Seifried, MA Jakupec… - Journal of inorganic …, 2006 - Elsevier
Indazolium trans-[tetrachlorobis (1H-indazole) ruthenate (III)](KP1019 or FFC14A) is just the
second ruthenium-based anticancer agent after NAMI-A which was developed to the stage …

NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application

R Trondl, P Heffeter, CR Kowol, MA Jakupec… - Chemical …, 2014 - pubs.rsc.org
NKP-1339 is the first-in-class ruthenium-based anticancer drug in clinical development
against solid cancer and has recently been studied successfully in a phase I clinical trial …

Combination of Ru (II) complexes and light: new frontiers in cancer therapy

C Mari, V Pierroz, S Ferrari, G Gasser - Chemical science, 2015 - pubs.rsc.org
The synergistic action of light, oxygen and a photosensitizer (PS) has found applications for
decades in medicine under the name of photodynamic therapy (PDT) for the treatment of …

KP1019, a new redox‐active anticancer agent–Preclinical development and results of a clinical phase I study in tumor patients

CG Hartinger, MA Jakupec… - Chemistry & …, 2008 - Wiley Online Library
The promising drug candidate indazolium trans‐[tetrachlorobis (1H‐indazole) ruthenate
(III)](KP1019) is the second Ru‐based anticancer agent to enter clinical trials. In this review …

The development of RAPTA compounds for the treatment of tumors

BS Murray, MV Babak, CG Hartinger… - Coordination Chemistry …, 2016 - Elsevier
Abstract Ruthenium (II)-arene RAPTA-type compounds have been extensively explored for
their medicinal properties. Herein a comprehensive review of this class of compounds is …

Thirty years of the drug candidate NAMI‐A and the myths in the field of ruthenium anticancer compounds: a personal perspective

E Alessio - European Journal of Inorganic Chemistry, 2017 - Wiley Online Library
As anticipated in the title, this contribution is basically divided into two, strictly connected,
parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 …

Redox activation of metal-based prodrugs as a strategy for drug delivery

N Graf, SJ Lippard - Advanced drug delivery reviews, 2012 - Elsevier
This review provides an overview of metal-based anticancer drugs and drug candidates. In
particular, we focus on metal complexes that can be activated in the reducing environment of …

Ruthenium-based chemotherapeutics: are they ready for prime time?

ES Antonarakis, A Emadi - Cancer chemotherapy and pharmacology, 2010 - Springer
Since the discovery of cis-platinum, many transition metal complexes have been
synthesized and assayed for antineoplastic activity. In recent years, ruthenium-based …

Non platinum metal complexes as anti‐cancer drugs

I Ott, R Gust - Archiv der Pharmazie: An International Journal …, 2007 - Wiley Online Library
The development of metal complexes with platinum central atoms such as cisplatin or
carboplatin had an enormous impact on current cancer chemotherapy. However, the …